Treatment options in patients with pancreatic cancer: A 10-year multicenter epidemiological investigation in China

Table 4 Comparison of efficacy of different chemotherapy regimens

Adjuvant therapy (case number)		P value	HR (95%CI)	Relapse/metastasis treatment (case number)		P value	HR (95%CI)
1. Fluorouracil1	Monotherapy (15)		1.00	1. First-line	Gemcitabine monotherapy (40)		1.00
	Combination (73)	0.163	0.40 (0. 11-1.44)		Tegafur + gemcitabine + platinum (2)	0.343	0.38 (0.05-2.82)
2. Gemcitabine	Monotherapy (27)		1.00		Tegafur + monotherapy (9)	0.008	0.20 (0.06-0.66)
	Combination (80)	0.019	0.40 (0.18-0.86)		Gemcitabine + albumin-bound paclitaxel (20)	0.929	0.97 (0.54-1.76)
3. All regimens	Gemcitabine monotherapy (27)		1.00		Gemcitabine + cisplatin (18)	0.015	0.16 (0.04-0.70)
	Fluorouracil monotherapy (14)	0.720	0.79 (0.22-2.89)		Gemcitabine + oxaliplatin (53)	0.788	0.94 (0.58-1.52)
	Gemcitabine + fluorouracil (38)	0.028	0.35 (0.14-0.89)		Gemcitabine + 5-FU (15)	0.577	0.80 (0.37-1.74)
	Gemcitabine + platinum (39)	0.998	0.48 (0.20-1.19)		Gemcitabine + capecitabine (21)	0.912	0.97 (0.54-1.74)
	Gemcitabine + fluorouracil + platinum2 (6)	0.113	0.19 (0.02-1.51)		Tegafur + gemcitabine + platinum (12)	0.033	0.32 (0.11-0.91)
	Fluorouracil + platinum (21)	0.117	0.29 (0.08-1.06)		FOLFIRINOX (8)	0.854	0.93 (0.42-2.07)
4. Gemcitabine-based regimens	Monotherapy (27)		1.0	2. Second-line	Tegafur monotherapy (6)		1.00
	Gemcitabine + fluorouracil (38)	0.030	0.35(0.14-0.90)		Tegafur + oxaliplatin (9)	0.278	0.49 (0.14-1.76)
	Gemcitabine + platinum (39)	0.113	0.48 (0.20-1.19)		Gemcitabine + albumin-bound paclitaxel (2)	0.343	0.35 (0.04-3.08)
	Gemcitabine + fluorouracil + platinum (6)	0.124	0.20 (0.02-1.56)		Gemcitabine + oxaliplatin (3)	0.825	1.28 (0.14-11.52)
5. Fluorouracil-based regimens	Monotherapy (14)		1.00		FOLFIRINOX (5)	0.099	0.10 (0.01-1.27)
	Gemcitabine + fluorouracil (38)	0.219	0.43 (0.11-1.65)		Oxaliplatin + 5-FU + catarabine (6)	0.943	1.05 (0.31-3.56)
	Gemcitabine + fluorouracil + platinum (6)	0.212	0.24 (0.02-2.28)		Oxaliplatin + catarabine (6)	0.892	1.10 (0.29-4.16)
	Fluorouracil + platinum (21)	0.217	0.36 (0.07-1.82)

¹Fluorouracil includes tegafur, 5-FU, and capecitabine therapies.

²Platinum includes cis-platinum and oxaliplatin.

Bold values indicated P < 0.05, which was statistically significant. The confounding factors identified in Table 2 were controlled, including age, body mass index, and history of pancreatitis. The treatment options and patient stages were not controlled because the stages and choices of patients were differentiated through different chemotherapy stages. CI: Confidence interval; HR: Hazard ratio.